Gamble Jones Investment Counsel’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $13M | Sell |
143,327
-2,062
| -1% | -$174K | 0.98% | 25 |
|
|
2022
Q3 | $11.1M | Buy |
145,389
+674
| +0.5% | +$55.9K | 0.9% | 26 |
|
|
2022
Q2 | $12.2M | Sell |
144,715
-2,229
| -2% | -$196K | 0.9% | 26 |
|
|
2022
Q1 | $12.9M | Sell |
146,944
-962
| -0.7% | -$83.3K | 0.8% | 30 |
|
|
2021
Q4 | $12.9M | Buy |
147,906
+639
| +0.4% | +$53.1K | 0.77% | 29 |
|
|
2021
Q3 | $12M | Buy |
147,267
+919
| +0.6% | +$82.7K | 0.79% | 29 |
|
|
2021
Q2 | $13.4M | Sell |
146,348
-80
| -0.1% | -$7.12K | 0.87% | 26 |
|
|
2021
Q1 | $12.5M | Buy |
146,428
+2,798
| +2% | +$251K | 0.84% | 26 |
|
|
2020
Q4 | $13.6M | Buy |
143,630
+355
| +0.2% | +$31K | 0.92% | 25 |
|
|
2020
Q3 | $12.5M | Sell |
143,275
-1,504
| -1% | -$130K | 0.91% | 25 |
|
|
2020
Q2 | $12.6M | Sell |
144,779
-1,158
| -0.8% | -$100K | 1.01% | 26 |
|
|
2020
Q1 | $12M | Sell |
145,937
-1,267
| -0.9% | -$113K | 1.11% | 21 |
|
|
2019
Q4 | $13.9M | Sell |
147,204
-2,108
| -1% | -$189K | 1.09% | 21 |
|
|
2019
Q3 | $13M | Buy |
149,312
+1,845
| +1% | +$166K | 1.07% | 22 |
|
|
2019
Q2 | $13.5M | Sell |
147,467
-15,991
| -10% | -$1.35M | 1.15% | 22 |
|
|
2019
Q1 | $14.1M | Buy |
163,458
+5,259
| +3% | +$422K | 1.25% | 19 |
|
|
2018
Q4 | $12.2M | Buy |
158,199
+762
| +0.5% | +$59.3K | 1.22% | 19 |
|
|
2018
Q3 | $12.2M | Buy |
157,437
+8,410
| +6% | +$622K | 1.12% | 21 |
|
|
2018
Q2 | $10.1M | Buy |
149,027
+2,038
| +1% | +$141K | 1.01% | 20 |
|
|
2018
Q1 | $10.6M | Buy |
146,989
+21,141
| +17% | +$1.61M | 1.06% | 19 |
|
|
2017
Q4 | $9.47M | Buy |
125,848
+195
| +0.2% | +$14.7K | 0.9% | 20 |
|
|
2017
Q3 | $9.67M | Sell |
125,653
-2,585
| -2% | -$195K | 0.99% | 18 |
|
|
2017
Q2 | $9.59M | Sell |
128,238
-7,153
| -5% | -$507K | 1% | 20 |
|
|
2017
Q1 | $9.01M | Sell |
135,391
-462
| -0.3% | -$30.8K | 0.95% | 21 |
|
|
2016
Q4 | $8.87M | Sell |
135,853
-617
| -0.5% | -$40K | 0.98% | 20 |
|
|
2016
Q3 | $9.66M | Buy |
136,470
+5,602
| +4% | +$408K | 1.05% | 19 |
|
|
2016
Q2 | $9.68M | Buy |
130,868
+54,467
| +71% | +$3.76M | 1.05% | 18 |
|
|
2016
Q1 | $4.96M | Sell |
76,401
-826
| -1% | -$56.2K | 0.55% | 40 |
|
|
2015
Q4 | $5.95M | Sell |
77,227
-2,442
| -3% | -$194K | 0.66% | 37 |
|
|
2015
Q3 | $6.56M | Sell |
79,669
-5,667
| -7% | -$504K | 0.76% | 32 |
|
|
2015
Q2 | $7.52M | Sell |
85,336
-1,897
| -2% | -$174K | 0.78% | 30 |
|
|
2015
Q1 | $7.71M | Sell |
87,233
-1,836
| -2% | -$163K | 0.8% | 28 |
|
|
2014
Q4 | $7.39M | Sell |
89,069
-1,378
| -2% | -$114K | 0.76% | 30 |
|
|
2014
Q3 | $7.63M | Buy |
90,447
+897
| +1% | +$72.6K | 0.84% | 24 |
|
|
2014
Q2 | $7.26M | Sell |
89,550
-2,667
| -3% | -$210K | 0.81% | 27 |
|
|
2014
Q1 | $7.03M | Sell |
92,217
-2,567
| -3% | -$187K | 0.82% | 27 |
|
|
2013
Q4 | $6.83M | Sell |
94,784
-2,587
| -3% | -$180K | 0.8% | 25 |
|
|
2013
Q3 | $6.69M | Sell |
97,371
-3,002
| -3% | -$199K | 0.86% | 25 |
|
|
2013
Q2 | $6.36M | Buy |
+100,373
| New | +$6.53M | 0.84% | 23 |
|
Other funds holding NVS
Gamble Jones Investment Counsel's NVS Position: Q4 2022 in Review
Gamble Jones Investment Counsel reduced its Novartis (NVS) stake by 1.4% in Q4 2022, selling an estimated $174K and leaving 143,327 shares worth $13M. The position accounts for 0.98% of the portfolio, ranked #25.
Gamble Jones Investment Counsel first reported a position in NVS in Q2 2013 and has held it in 39 quarters since. The position peaked at $14.1M in Q1 2019. 1,183 funds tracked by Wall St. Rank hold NVS as of Q4 2022.
- Gamble Jones Investment Counsel held 143,327 shares of Novartis worth $13M as of Q4 2022.
- Gamble Jones Investment Counsel sold 2,062 Novartis shares in Q4 2022, an estimated $174K.
- Novartis made up 0.98% of Gamble Jones Investment Counsel's portfolio in Q4 2022, its #25 holding.
- Gamble Jones Investment Counsel first reported a position in Novartis in Q2 2013 and has held it in 39 quarters since.
- Gamble Jones Investment Counsel's Novartis position peaked at $14.1M in Q1 2019.
- 1,183 funds tracked by Wall St. Rank held Novartis as of Q4 2022.
Based on Gamble Jones Investment Counsel's 13F filing for Q4 2022, filed 8 Feb 2023.